Maria Cristina Cesana, Debora Vicini, Simona Ruisi, Martina Fantauzzi, Antonio Pellegrino
{"title":"Metabolic and Weight Observations in Four Women Using Triphasic Norgestimate/Ethinylestradiol: A Six-month Descriptive Case Series.","authors":"Maria Cristina Cesana, Debora Vicini, Simona Ruisi, Martina Fantauzzi, Antonio Pellegrino","doi":"10.2147/OAJC.S604855","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Triphasic combined oral contraceptives (COCs) containing norgestimate and ethinylestradiol are established therapeutic options. Previous studies and reviews have described their metabolic profile, but contemporary routine-practice descriptions remain limited. This report was not designed to test efficacy or to generate population-level evidence.</p><p><strong>Objective: </strong>To describe short-term changes in selected metabolic and clinical parameters over six months in four women using a triphasic norgestimate/35 µg ethinylestradiol COC.</p><p><strong>Patients and methods: </strong>This retrospective descriptive case series included four women of reproductive age, without known metabolic disorders, who initiated triphasic norgestimate/35 µg ethinylestradiol in routine clinical practice and had complete records at baseline, 3 months, and 6 months. Fasting glucose, triglycerides, total cholesterol, LDL/HDL ratio, blood pressure, and body weight were extracted from clinical records. Results are summarized descriptively as medians with ranges and patient-level changes. No inferential analyses were planned or performed.</p><p><strong>Results: </strong>Fasting glycaemia remained within the physiological range in all four patients at each time point. Median triglycerides increased from 98 mg/dL at baseline to 123 mg/dL at 3 months and decreased to 88 mg/dL at 6 months; one patient had a value of 151 mg/dL at 3 months. Median total cholesterol increased from 173 mg/dL at baseline to 195.5 mg/dL at 6 months, with two patients above 200 mg/dL at 6 months. LDL/HDL ratios remained below 2 at 6 months, although individual changes were heterogeneous. Body weight showed small individual fluctuations from baseline to 6 months (-2 to +1 kg).</p><p><strong>Conclusion: </strong>This four-patient retrospective case series provides descriptive short-term observations only. The findings should not be interpreted as evidence of metabolic efficacy, safety, or generalizability. They are hypothesis-generating and require evaluation in larger prospective studies with standardized follow-up and assessment of potential confounders.</p>","PeriodicalId":74348,"journal":{"name":"Open access journal of contraception","volume":"17 ","pages":"604855"},"PeriodicalIF":2.8000,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open access journal of contraception","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OAJC.S604855","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Triphasic combined oral contraceptives (COCs) containing norgestimate and ethinylestradiol are established therapeutic options. Previous studies and reviews have described their metabolic profile, but contemporary routine-practice descriptions remain limited. This report was not designed to test efficacy or to generate population-level evidence.
Objective: To describe short-term changes in selected metabolic and clinical parameters over six months in four women using a triphasic norgestimate/35 µg ethinylestradiol COC.
Patients and methods: This retrospective descriptive case series included four women of reproductive age, without known metabolic disorders, who initiated triphasic norgestimate/35 µg ethinylestradiol in routine clinical practice and had complete records at baseline, 3 months, and 6 months. Fasting glucose, triglycerides, total cholesterol, LDL/HDL ratio, blood pressure, and body weight were extracted from clinical records. Results are summarized descriptively as medians with ranges and patient-level changes. No inferential analyses were planned or performed.
Results: Fasting glycaemia remained within the physiological range in all four patients at each time point. Median triglycerides increased from 98 mg/dL at baseline to 123 mg/dL at 3 months and decreased to 88 mg/dL at 6 months; one patient had a value of 151 mg/dL at 3 months. Median total cholesterol increased from 173 mg/dL at baseline to 195.5 mg/dL at 6 months, with two patients above 200 mg/dL at 6 months. LDL/HDL ratios remained below 2 at 6 months, although individual changes were heterogeneous. Body weight showed small individual fluctuations from baseline to 6 months (-2 to +1 kg).
Conclusion: This four-patient retrospective case series provides descriptive short-term observations only. The findings should not be interpreted as evidence of metabolic efficacy, safety, or generalizability. They are hypothesis-generating and require evaluation in larger prospective studies with standardized follow-up and assessment of potential confounders.